Granite Point Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Granite Point Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100,000	Closed	-$985K	–	193
2021 Q2	$985K	Sell	100,000 -100,000	-50%	-$984K	0.04%	122
2021 Q1	$2M	Sell	200,000 -182,693	-48%	-$1.88M	0.07%	91
2020 Q4	$3.85M	Buy	+382,693	New	+$3.85M	0.2%	46

Other funds holding EUCR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Granite Point Capital Management's EUCR Position: Q3 2021 in Review

Granite Point Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q3 2021, closing a stake of 100,000 shares — an estimated $985K sold.

Granite Point Capital Management first reported a position in EUCR in Q4 2020 and held it in 3 quarters. The position peaked at $3.85M in Q4 2020. 34 funds tracked by Wall St. Rank hold EUCR as of Q3 2021.

Granite Point Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q3 2021 after selling out during the quarter.
Granite Point Capital Management sold 100,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q3 2021, an estimated $985K.
Granite Point Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2020 and held it in 3 quarters.
Granite Point Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $3.85M in Q4 2020.
34 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q3 2021.

Based on Granite Point Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.